Junevity expands seed funding to $20 million for JUN_01 obesity program

Junevity

Junevity announced an expanded seed round bringing total funding to $20 million. The capital will advance JUN_01, an siRNA candidate for obesity and type 2 diabetes, toward first-in-human trials in H2 2026.